12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Canagliflozin: Phase III data

Data from a subgroup of 1,718 Type II diabetics who were receiving insulin in the double-blind, international Phase III CANVAS (DIA3008) trial showed that once-daily 100 and 300 mg oral canagliflozin as an add-on to insulin each met the subgroup's primary endpoint of reducing HbA1c from baseline to week 18 vs. placebo (placebo-adjusted reductions of 0.65% and 0.73%, respectively, p<0.001 for both). On secondary endpoints, low- and high-dose canagliflozin led to significantly greater placebo-adjusted reductions in body weight (1.9% and 2.4%, p<0.001 for both), fasting plasma glucose (FPG) (1.25...

Read the full 424 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >